NTS 104
Alternative Names: NTS-104; NTS-1104Latest Information Update: 28 Jan 2024
At a glance
- Originator Emory University
- Developer NeuroTrauma Sciences
- Class Anti-inflammatories; Neuroprotectants; Small molecules; Vascular disorder therapies
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Stroke
- Research Subdural haematoma
- No development reported Traumatic brain injuries
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in USA
- 12 Jul 2023 Early research in Subdural haematoma in USA (unspecified route) (NeuroTrauma Sciences pipeline; July 2023)
- 01 Jun 2023 NeuroTrauma Sciences plans a phase II trial for Stroke